FRONTIER BIOTECHNOLOGIES Inc.

Press Releases

   
Home>Media

Aikening® (albuvirtide) Granted Approval by the Food and Drug Administration in China for Use as An Intravenous Bolus Injection Improves Convenience and Compliance

Frontier Biotechnologies announced in October 2022, it has obtained approval from the Food and Drug Administration in China for Aikening® (albuvirtide) for use as an intravenous bolus injection, as an additional route of administration.The current route of administration for Aikening® is v...
  • 2022-11-04  14:59:38
details>

Aikening® Unveiled at the Malaysian HIV Forum After Obtaining Marketing Authorization in Malaysia

Frontier Biotechnologies obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the National Pharmaceutical Regulatory Agency of Malaysia in September 2022. Subsequently, Frontier Biotech partnered Pahang Pharmacy and particip...
  • 2022-10-15  16:18:45
details>

"Our drug is now an important treatment for HIV patients in China"

  • 2022-10-03  16:15:16
details>

Frontier Biotechnologies Announces Approval of Clinical Trial Application for a novel FB2001 Nebulized Aerosol Inhalation formulary to treat COVID-19

Recently, Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) received the "Pharmaceutical Clinical Trial Approval Notice" issued by the National Medical Products Administration. The study of FB2001 nebulization inhalation will enroll patients with mil...
  • 2022-09-27  16:14:12
details>

Dr. Changjin Wang, CEO at Frontier Biotechnologies, Shares Insights on P-I Results of its Coronavirus Mpro Inhibitor

  • 2022-09-19  15:52:23
details>

Frontier Biotechnologies Inc. have been included in the list of “China’s Top 30 Small Molecule Pharmaceutical Companies Innovation”

On September 16, 2022, the "2021 China Biopharmaceutical Enterprise Innovation Top 100 Series List" officially announced, Frontier Biotechnologies Inc. (stock code "688221.SH") was once again successfully included as "Chinas Top 30 Small Molecule Pharmaceutical Enterprises I...
  • 2022-09-17  14:57:06
details>

Aikening® (albuvirtide) Granted Marketing Authorisation by Malaysia’s National Pharmaceutical Regulatory Agency for the Treatment of HIV-1

Frontier Biotechnologies announced it obtained approval for Aikening® (albuvirtide for injection), the first long-acting fusion inhibitor treatment for HIV, from the National Pharmaceutical Regulatory Agency of Malaysia.Aikening® is indicated to be used in combination with other antiretrov...
  • 2022-09-09  14:45:56
details>

Frontier Biotechnologies announces collaboration with Keyuan, a pharmaceutical distribution company under Shanghai Pharmaceutical Group Cooperation on the commercialization of Aikening®

On August 11, 2022, Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as Frontier Biotech or Company, stock code: 688221. SH), and Shanghai Pharmaceutical Group (stock code: 601607. SH, 02607.HK) Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to ...
  • 2022-08-12  13:38:57
details>

Frontier Biotechnologies announced phase I clinical result of COVID-19 treatment FB2001 at the International Conference on Emerging Infectious Diseases (ICEID)

On August 8, local time in the United States, Frontier Biotechnologies (Nanjing) Co., Ltd. (hereinafter referred to as the "Company", stock code: 688221. SH) announced the results of the Phase I clinical research of the small molecule drug FB2001 (common name: Bofutrelvir) at the 11th Inte...
  • 2022-08-09  13:37:44
details>

Frontier Biotechnologies signed a strategic cooperation agreement with Kangsheng Global to jointly develop the infectious disease diagnosis and treatment market

Frontier Biotech and Kangsheng Global have reached a number of cooperation Consensus on the promotion of anti-infection diagnostic testing, and are committed to jointly promoting the improvement of the diagnosis and treatment level of infectious diseases in China. This partnership ensures both compa...
  • 2022-08-08  13:35:02
details>

Frontier Biotechnologies was awarded the "2022 China Biopharmaceutical Industry Value List - Top 10 Most Growing Small Molecule Innovative Pharmaceutical Enterprises"

On August 4, 2022, the 2022 China Biopharmaceutical Industry Value List Awards Ceremony was held in Suzhou, and Frontier Biotechnologies Inc. (stock code "688221.SH") was awarded the "2022 China Biopharmaceutical Industry Value List - Top 10 Most Growing Small Molecule Innovative Phar...
  • 2022-08-05  13:33:51
details>

First Scientific Education Collaboration with Ministry of Commerce of the People’s Republic of China and Beijing Holley-Cotec Pharamceuticals for Officials of Developing Countries

Frontier Biotechnologies was invited by the Ministry of Commerce of the People’s Republic of China and Beijing Holley-Cotec Pharamceuticals Co. Ltd to deliver a training lecture titled “HIV Treatment Trends and Introduction of Albuvirtide” at the “Seminar for Officials of Developing Countries”, incl...
  • 2022-07-25  15:46:58
details>

Develop Innovative Therapies to Better Human Lives

Frontier Biotechnologies Inc.（Nanjing）
Medicalinfo@frontierbiotech.com
jubao@frontierbiotech.com
Adverse events report mailbox：pv@frontierbiotech.com
Copyright © 2016 Corporation All Rights ReservedFrontier Biotechnologies Inc.
Full Prescribing Information | Introduction for Use | About Frontier

This site is for informational purposes only
and is intended for Healthcare Professionals.

Are you a Healthcare Professional?

I am a licensed Healthcare Professional I am a Patient or Caregiver